| Literature DB >> 10676768 |
Abstract
Recombinant hematopoietic growth factors were introduced into clinical practice a decade ago: erythropoietin in 1989, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in 1991, and interleukin-11 in 1997. The role of these agents in supportive therapy for children with cancer is still under considerable evaluation. This pediatric-based review summarizes current clinical applications, practice guidelines, and practice patterns for hematopoietic growth factors in the supportive care of children with cancer. It also discusses ongoing controversies and unanswered questions.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10676768 DOI: 10.1097/00008480-200002000-00003
Source DB: PubMed Journal: Curr Opin Pediatr ISSN: 1040-8703 Impact factor: 2.856